SingleB® Hybridoma Protein Expression

Hu-Mouse SingleB® mAb Discovery Service

As "non-self" substances, antibody drugs generated from non-human animals usually trigger human immune responses when administered to human, and produce anti-drug antibodies (ADAs) that in many cases seriously affect the safety and effectiveness of drugs, limiting their clinical outcomes and, in the worst cases, leading to project termination or marketed drug withdrawal.

Therefore, it is urgent to reduce the immunogenicity of therapeutic antibodies, which has been achieved to some degree through either antibody humanization or antibody generation from transgenic mice or fully human libraries. As of February, 2021, FDA has approved 39 fully human mAb, of which most are from transgenic mice. However, the abovementioned approaches each have drawbacks, such as residual immunogenicity, impaired affinity and develop ability, or insufficient efficacy.

DetaiBio integrated its proprietary SingleB® mAb discovery technology with an up-to-date fully-humanized transgenic mice model to fulfill fast, fully human antibody discovery. By directly screening primary memory B cells and plasma cells harvested from immunized, fully-humanized transgenic mice, we deliver FACS-validated, fully-humanized mAbs that areofcomparable affinity with its wild type counterparts for you to minimize the immunogenicity risk of antibody drug.

CAMouseHG: Fully-humanized Transgenic Mouse

CAMouseHG was generated by in situ replacing murine antibody-coding gene fragments with 70 human Ig V-region genes for expressing human antibody molecules in mice. The random recombination of separate V, D, and J gene segments and human/mouse Ig temporal and spatial expression technology enable the formation of mouse IgM BCR structure in the early stage of B cell development, and ensure the normal maturation of mouse B cells thereafter.

Service Features

“1+1” Double Guarantee

  • PBC&MBC double screening, double guarantee

Natural Maturation

  • In-vivo natural maturation
  • Natural pairing of heavy and light chains

High Probability

  • High antibody diversity
  • Higher probability of discovery of unique epitopes

High Delivery

  • At least 50 FACS binders
  • Reserve hundreds of clones



Stage Ⅰ Animal Immunization
  • Antigen preparation (optional)
  • Animal immunization
  • Serum titer test
2-4 weeks Premium Package

  • FACs binders >50
  • Ensure sequence diversity
  • Antibody sequence and expression plasmid
  • CoA

Economic Package

  • 5-10 ELISA positive clones
  • Antibody sequence and expression plasmid
  • Select one strain purified 1 mg antibody
  • CoA
Stage Ⅱ “1+1”Double Screening
  • MBC screening
  • PBC screening
1 day
Stage Ⅲ BGE® HTP Expression & Functional Test
  • ELISA Assay
  • FACs Assay
1-2 weeks
Stage Ⅳ Monoclonal Antibody Gene Sequencing
  • HTP gene screening
1 week
Stage Ⅴ Expression and Purification of Recombinant Antibody (optional)
  • Transfection level plasmid preparation
  • Transient transfection expression
  • HTP purification
  • Endotoxin control
For enquiry

Advantages of Human Antibody

Position of HumanizationC-regionRegion except CDR or SDRAll regions
Degree of Humanization60%-70%90%-95%100%

Advantages of SingleB®

DetaiBio SingleB®Phage LibraryBeacon
LimitationHigh technical thresholdLimited by natural library capacityHigh price & Low throughput
Source of AntibodyMBC & PBCMBC & PBCPBC
Heavy & Light Chain PairingNatural pairingUnnatural pairingNatural pairing
Throughput x DiversityHighMediumLow
Timeline1.5 months1-2 weeks1-2 months
DeliverablesFull length antibody sequence & Recombinant plasmidscFv、Fab、VHH sequence & Recombinant plasmid (additional affinity maturation needed)Antibody sequence & Recombinant plasmid

Related Service